Wedbush hikes target on Receptos

Market chatter suggests Wedbush is out with a price target hike to $44 (from $26) for Receptos (RCPT -0.8%).

Rationale: Optimism for RPC1063's potential in IBD,

BMO was out with a similarly bullish call ($41 target) earlier this month, highlighting development of RPC1063 in Relapsing Multiple Sclerosis.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs